The latest data of GT19715, a new C-Myc/GSPT1 dual-target degrader, was presented at ASH 2022 in an oral presentation

Pioneer Pharmaceutical (stock code: 9939.
HK), a biopharmaceutical company focused on the development and industrialization of potential first-in-class and best-in-class innovative drugs, announced that the latest results of its self-developed novel C-Myc/GSPT1 dual-target degrader GT19715 have been selected for an oral presentation at the 2022 American Society of Hematology (ASH 2022), and the relevant abstracts can be found
on ASH's website.

The American Society of Hematology Annual Meeting is the world's largest international event in the field of hematology, attracting basic, translational and clinical researchers
in hematology each year.
ASH 2022 will be held
from Saturday, December 10 to Tuesday, December 13, 2022 in New Orleans, Louisiana, USA.

Oncoprotein Myc dysregulation is present in 70% of human cancers, mainly manifested by increased expression levels and enhanced activity to promote the progression of
cancers, including leukemia and lymphoma.
Translocations of MYC gene rearrangements in Burkitt lymphoma (BL) are most common (100%)
.
High expression of MYC has also been observed in acute myeloid leukemia (AML), including in patients
with AML with TP53 mutations or venetoclax (ven) resistance.
Despite recent advances in the treatment of AML, both AML patients have a very poor clinical prognosis
.

Pioneer Pharmaceuticals and Michael Andreeff, professor of leukemia at the University of Texas MD Anderson Cancer Center, studied the preclinical activity
of the novel C-Myc/GSPT1 dual-target degrader GT19715 in drug-resistant AML models.

Using single-cell mass spectrometry flow cytometry, the researchers found increased levels of c-Myc protein in poorly differentiated CD34+ AML cells compared to normal bone marrow CD34+ cells
.
GT19715 showed good anti-leukemia effect in AML cells with TP53 mutations, especially in poorly differentiated CD34+ cells; and in Daudi Burkitt lymphoma and venetoclax-resistant AML model mice, GT19715 treatment eliminated lymphoma and leukemia cells
.
The findings will be presented orally by Dr.
Yuki Nishida from Michael Andreeff's team on December 10
, 2022.

Dr.
Youzhi Tong, Founder, Chairman and CEO of Pioneer Pharmaceuticals, said, "We are very pleased that the latest results of the new c-Myc/GSPT1 dual-target degrader GT19715 have been selected as an oral presentation for this year's ASH Annual Meeting, which demonstrates the recognition of the therapeutic potential of GT19715 by the international hematology community
.
We will accelerate the progress of GT19715 into the clinical phase and hope to bring more innovative treatment options
to patients with unmet needs.
" "

Dr.
Andreeff said, "We are very pleased to present preclinical activity data for GT19715 at this year's ASH Annual Meeting, particularly in
MYC-driven leukemia and lymphoma.
MYC controls the oncogenic processes of various cancer initiation and progression, and although there have been many attempts to target MYC or its pathways, it has long been one of
the "undruggable" targets in cancer treatment.
We reported the inhibitory effect of p53 reactivation on MYC at the ASH Annual Meeting last year, but now we have the first compound that successfully degrades MYC itself, showing very promising early activity that should also be applied to other MYC-driven malignancies
.
"

■ Oral presentation

C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53-Independent Cell Death in Acute Myeloid Leukemia and Lymphomas

Degradation-targeted C-MYC: GT19715, a novel C-MYC/GSPT1 dual-target degrader, induces TP53-independent cell death in acute myeloid leukemia and lymphoma

Abstract number: 199

Session 604, Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Targeted Protein Degradation and Emerging Small Molecule Inhibitors in Myeloid Neoplasms Molecular Pharmacology and Drug Resistance: Myeloid Tumors: Targeting Protein Degradation and Emerging Small Molecule Inhibitors in Myeloid Tumors

Form of presentation: Oral presentation

When: December 10, 2022 at 2 p.
m.
ET

Summary link: https://ash.
confex.
com/ash/2022/webprogram/Paper164968.
html